Cannabidiol has shown to decrease activity of the
limbic system[11] and to decrease social isolation induced by
THC.
[12] It's also shown that Cannabidiol reduces anxiety in
social anxiety disorder.
[13] [14] In April 2005, Canadian authorities approved the marketing of
Sativex, a mouth spray for
multiple sclerosis to alleviate pain. Sativex contains tetrahydrocannabinol together with cannabidiol. It is marketed in
Canada by GW Pharmaceuticals.
In 1985 a single case study suggested that CBD may be effective in the management of levodopa-induced dyskinesia in a Parkinson's Disease patient.
[15]
Studies have shown that CBD may reduce
schizophrenic symptoms in patients, likely due to their apparent ability to stabilize disrupted or disabled
NMDA receptor pathways in the brain, which are shared and sometimes contested by
norepinephrine and
GABA.
[6][16] Leweke
et al. performed a double blind, 4 week, explorative controlled clinical trial to compare the effects of purified cannabidiol and the atypical antipsychotic
amisulpride on improving the symptoms of schizophrenia in 42 patients with acute paranoid schizophrenia. Both treatments were associated with a significant decrease of psychotic symptoms after 2 and 4 weeks as assessed by
Brief Psychiatric Rating Scale and
Positive and Negative Syndrome Scale. While there was no statistical difference between the two treatment groups, cannabidiol induced significantly fewer side effects (
extrapyramidal symptoms, increase in prolactin, weight gain) when compared to amisulpride.
[17]
